Promising personalized therapeutic options for diffuse large B-cell lymphoma subtypes with oncogene addictions

Clinical Cancer Research

Volumn 18, Issue 17, 2012, Pages 4538-4548

  Steinhardt, James J ^a   Gartenhaus, Ronald B ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b BALTIMORE VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; BREAKPOINT CLUSTER REGION PROTEIN; CYTIDINE DEAMINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN HEAVY CHAIN; INTERFERON REGULATORY FACTOR 4; PROTEIN BCL 2; PROTEIN BCL 6; PROTEIN BCL W; PROTEIN BCL XL; RAG1 PROTEIN; TOLL LIKE RECEPTOR;

CELL MATURATION; GENOTYPE; GERMINAL CENTER; HUMAN; IMMUNE RESPONSE; LARGE CELL LYMPHOMA; ONCOGENE; OXIDATIVE PHOSPHORYLATION; PERSONALIZED MEDICINE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SOMATIC HYPERMUTATION;

DNA-BINDING PROTEINS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOTYPE; HUMANS; INDIVIDUALIZED MEDICINE; LYMPHOMA, LARGE B-CELL, DIFFUSE; NF-KAPPA B; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84865773025     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0217     Document Type: Review

References (140)

1. Abramson JS, Shipp MA. Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood 2005;106:1164-74.
2. Luce JK, Gamble JF, Wilson HE, Monto RW, Isaacs BL, Palmer RL, et al. Combined cyclophosphamide, vincristine and prednisone therapy of malignant lymphoma. Cancer 1971;28:306-17.
3. Rodriguez V, Cabanillas F, Burgess MA, McKelvey EM, Valdivieso M, Bodey G, et al. Combination chemotherapy ("CHOP-Bleo") in advanced (non-Hodgkin) malignant lymphoma. Blood 1977;49: 325-33.
4. Carbone PP, Spurr C. Management of patients with malignant lymphoma: a comparative study with cyclophosphamide and vinca alkaloids. Cancer Res 1968;28:811-22.
5. Carbone PP, Bono V, Frei E III, Brindley CO. Clinical studies with vincristine. Blood 1967;21:640-7.
6. Hall TC, Choi OS, Abadi A, Krant MJ. High-dose corticoid therapy in Hodgkin's disease and other lymphomas. Ann Intern Med 1967;66: 1144-53.
7. Coiffier B, Lepage E, Herbrecht R, Tilly H, Solal-Celigny P, Munck JN, et al. MabThera (rituximab) plus CHOP is superior to CHOP alone in elderly patients with diffuse large B-cell lymphoma (DLCL): interim results of a randomized GELA trial. Blood 2000;96:223A.
8. Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010;116:2040-5.
9. Weinstein IB. Addiction to oncogenes - the Achilles heel of cancer. Science 2002;297:63-4.
10. Soverini S, Colarossi S, Gnani A, Castagnetti F, Rosti G, Bosi C, et al. Resistance to dasatinib in Philadelphia-positive leukemia patients is mainly mediated by the presence or the selection of mutations at residues 315 and 317 in the Bcr-Abl kinase domain. Haematologica 2007;92:401-4.
11. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCRABL gene mutation or amplification. Science 2001 293:876-80.
12. Nagar B, Bornmann WG, Pellicena P, Schindler T, Veach DR, Miller WT, et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 2002;62:4236-43.
13. Singh A, Greninger P, Rhodes D, Koopman L, Violette S, Bardeesy N, et al. A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell 2009;15:489-500.
14. Kaelin WG Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 2005;5:689-98.
15. Ngo VN, Davis RE, Lamy L, Yu X, Zhao H, Lenz G, et al. A loss-offunction RNA interference screen for molecular targets in cancer. Nature 2006;441:106-10.
16. Oettinger MA, Schatz DG, Gorka C, Baltimore D. RAG-1 and RAG-2, adjacent genes that synergistically activate V(D)J recombination. Science 1990;248:1517-23.
17. Hozumi N, Tonegawa S. Evidence for somatic rearrangement of immunoglobulin genes coding for variable and constant regions. Proc Natl Acad Sci U S A 1976;73:3628-32.
18. Callén E, Jankovic M, Difilippantonio S, Daniel JA, Chen HT, Celeste A, et al. ATM prevents the persistence and propogation of chromosome breaks in lymphocytes. Cell 2007;130:63-75.
19. MacLennan IC. Germinal centers. Annu Rev Immunol 1994;12: 117-39.
20. Berek C, Berger A, Apel M. Maturation of the immune response in germinal centers. Cell 1991;67:1121-9.
21. Jacob J, Kelsoe G, Rajewsky K, Weiss U. Intraclonal generation of antibody mutants in germinal centres. Nature 1991;354:389-92.
22. KimS, Davis M, Sinn E, Patten P, Hood L. Antibody diversity: somatic hypermutation of rearranged VH genes. Cell 1981;27:573-81.
23. Kataoka T, Kawakami T, Takahashi N, Honjo T. Rearrangement of immunoglobulin gamma 1-chain gene and mechanism for heavychain class switch. Proc Natl Acad Sci U S A 1980;77:919-23.
24. Muramatsu M, Sankaranand VS, Anant S, Sugai M, Kinoshita K, Davidson NO, et al. Specific expression of activation-induced cytidine deaminase (AID), a novelmember of the RNA-editing deaminase family in germinal center B cells. J Biol Chem 1999;274:18470-6.
25. Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y, Honjo T. Class switch recombination and hypermuation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 2000;102:553-63.
26. Takizawa M, Tolarová H, Li Z, Dubois W, Lim S, Callen E, et al. AID expression levels determine the extent of cMyc oncogenic translocations and the incidence of B cell tumor development. J Exp Med 2008;205:1949-57.
27. Pasqualucci L, Bhagat G, Jankovic M, Compagno M, Smith P, Muramatsu M, et al. AID is required for germinal center-derived lymphomagenesis. Nat Genet 2008;40:108-12.
28. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-11.
29. Huang JZ, Sanger WG, Greiner TC, Staudt LM, Weisenburger DD, Pickering DL, et al. The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood 2002;99:2285-90.
30. Kikuchi A, Nakamura N, Kuze T, Sasaki Y, Abe M, Ohno H, et al. Characterization of de novo diffuse large B-cell lymphoma with a translocation of c-myc and immunoglobulin genes. Leuk Res 2008;32:1176-82.
31. Liu YJ, Mason DY, Johnson GD, Abbot S, Gregory CD, Hardie DL, et al. Germinal center cells express bcl-2 protein after activation by signals which prevent their entry into apoptosis. Eur J Immunol 1991;21:1905-10.
32. Shapiro-Shelef M, Lin KI, McHeyzer-Williams LJ, Liao J, McHeyzer- Williams MG, Calame K. Blimp-1 is required for the formation of immunoglobulin secreting plasma cells and pre-plasma memory B cells. Immunity 2003;19:607-20.
33. Reimold AM, Iwakoshi NN, Manis J, Vallabhajosyula P, Szomolanyi- Tsuda E, Gravallese EM, et al. Plasma cell differentiation requires the transcription factor XBP-1. Nature 2001;12:300-7.
34. Shaffer AL, Shapiro-Shelef M, Iwakoshi NN, Lee AH, Qian SB, Zhao H, et al. XBP1, downstream of BLIMP-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation. Immunity 2004;21:81-93.
35. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A 2003;100:9991-6.
36. Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001;194: 1861-74.
37. Pasqualucci L, Compagno M, Houldsworth J, Monti S, Grunn A, Nandula SV, et al. Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. J Exp Med 2006;203:311-7.
38. Cattoretti G, Shaknovich R, Smith PM, Jäck HM, Murty VV, Alobeid B. Stages of germinal center transit are defined by B cell transcription factor coexpression and relative abundance. J Immunol 2006;177: 6930-9.
39. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large Bcell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;1:275-82.
40. Dogan A, Bagdi E, Munson P, Isaacson PG. CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas. Am J Surg Pathol 2000;24:846-52.
41. Falini B, Fizzotti M, Pucciarini A, Bigerna B, Marafioti T, Gambacorta M, et al. A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood 2000;95:2084-92.
42. Jardin F, Sahota SS, Ruminy P, Parmentier F, Picquenot JM, Rainville V, et al. Novel Ig V gene features of t(14;18) and t(3;14) de novo diffuse large B-cell lymphoma displaying germinal center- B cell like and non-germinal center-B cell like markers. Leukemia 2006;20:2070-4.
43. Choi WW, Weisenburger DD, Greiner TC, Piris MA, Banham AH, Delabie J, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 2009;15:5494-502.
44. Shaknovich R, Geng H, Johnson NA, Tsikitas L, Cerchietti L, Greally JM, et al. DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma. Blood 2010;116:e81-9.
45. Lenz G, Wright GW, Emre NC, Kohlhammer H, Dave SS, Davis RE, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A 2008; 105:13520-5.
46. Monti S, Savage KJ, Kutok JL, Feuerhake F, Kurtin P, Mihm M, et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 2004;105:1851-61.
47. Küppers R, Dalla-Favera R. Mechanisms of chromosomal translocations in B cell lymphomas. Oncogene 2001;20:5580-94.
48. Pasqualucci L, Breschenko O, Niu H, Klein U, Basso K, Guglielmino R, et al. Molecular pathogenesis of non-Hodgkin's lymphoma: the role of Bcl-6. Leuk Lymphoma 2003;44:S5-12.
49. Allman D, Jain A, Dent A, Maile RR, Selvaggi T, Kehry MR, et al. BCL6 expression during B-cell activation. Blood 1996;87:5257-68.
50. Parekh S, Polo JM, Shaknovich R, Juszcynski P, Ranucolo SM, Yin Y, et al. BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms. Blood 2007;6: 2067-74.
51. Ahmad KF, Melnick A, Lax S, Bouchard D, Liu J, Kiang CL, et al. Mechanism of SMRT corepressor recruitment by the BCL6 BTB domain. Mol Cell 2003;12:1551-64.
52. Ranuncolo SM, Polo JM, Dierov J, Singer M, Kuo T, Greally J, et al. Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR. Nat Immunol 2007;8:705-14.
53. Phan RT, Dalla-Favera R. The BCL6 proto-oncogene suppresses p53 expression in germinal-center B cells. Nature 2004;432:635-9.
54. Fujita N, Jaye DL, Geigerman C, Akyildiz A, Mooney MR, Boss JM, et al. MTA3 and Mi-2/NuRD complex regulate cell fate during Blymphocyte differentiation. Cell 2004;119:75-86.
55. Saito M, Gao J, Basso K, Kitagawa Y, Smith PM, Bhagat G, et al. A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma. Cancer Cell 2007;12:280-92.
56. Ci W, Polo JM, Cerchietti L, Shaknovich R, Wang L, Yang SN, et al. The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL. Blood 2009;113:5536-48.
57. Basso K, Dalla-Favera R. BCL6: Master Regulator of the Germinal Center Reaction and KeyOncogene inBCell Lymphomagenesis. Adv Immunol 2010;105:193-210.
58. Polo JM, Juszczynski P, Monti S, Cerchietti L, Ye K, Greally JM, et al. Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas. Proc Natl Acad Sci U S A 2007;104:3207-12.
59. Polo JM, Dell'Oso T, Ranuncolo SM, Cerchietti L, Beck D, Da Silva GF, et al. Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. Nat Med 2004;10:1329-35.
60. Toney LM, Cattoretti G, Graf JA, Merghoub T, Pandolfi PP, Dalla- Favera R, et al. BCL-6 regulates chemokine gene transcription in macrophages. Nat Immunol 2007;1:214-20.
61. Cerchietti LC, Hatzi K, Caldas-Lopes E, Yang SN, Figueroa ME, Morin RD, et al. BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy. J Clin Invest 2010;120:4569-82.
62. Chattopadhyay A, Tate SA, Beswick RW, Wagner SD, Ko Ferrigno P. A peptide aptamer to antagonize BCL-6 function. Oncogene 2006;25:2223-33.
63. Parekh S, Prive GG, Melnick A. Therapeutic targeting of the BCL6 oncogene for diffuse large B-cell lymphomas. Leuk Lymphoma 2008;49:874-82.
64. Bakhshi A, Jensen JP, Goldman P, Wright JJ, McBride OW, Epstein AL, et al. Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell 1985;41:899-906.
65. Cleary ML, Sklar J. Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpointcluster region near a transcriptionally active locus on chromosome 18. Proc Natl Acad Sci U S A 1985;82:7439-43.
66. Tsujimoto Y, Cossman J, Jaffe E, CroceCM. Involvement of the bcl-2 gene in human follicular lymphoma. Science 1985;228:1440-3.
67. Iqbal J, Sanger WG, Horsman DE, Rosenwald A, Pickering DL, Dave B, et al. BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. Am J Pathol 2004;165:159-66.
68. Shaffer AL, Rosenwald A, Staudt LM. Decision making in the immune system: Lymphoid Malignancies: the dark side of B-cell differentiation. Nat Rev Immunol 2002;2:920-32.
69. Hockenbery D, Nũnez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348:334-6.
70. Wang X. The expanding role of mitochondria in apoptosis. Genes Dev 2001;15:2922-33.
71. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993;74:609-19.
72. Yang E, Zha J, Jockel J, Boise LH, Thompson CB, Korsmeyer SJ. Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell 1995;80:285-91.
73. Liu X, Kim CN, Yang J, Jemmerson R, Wang X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 1996;86:147-57.
74. Zou H, Henzel WJ, Liu X, Lutschg A, Wang X. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase 3. Cell 1997;90:405-13.
75. Wang K, Yin XM, Chao DT, Milliman CL, Korsmeyer SJ. BID: a novel BH3 domain-only death agonist. Genes Dev 1996;10:2859-69.
76. Yu J, Zhang L, Hwang PM, Kinzler KW, Vogelstein B. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell 2001;7: 673-82.
77. Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T, et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 2000;288:1053-8
78. Zong WX, Lindsten T, Ross AJ, MacGregor GR, Thompson CB. BH3- only proteins that bind pro-survival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak. Genes Dev 2001;15:1481-6.
79. Cheng EH, Wei MC, Weiler S, Flavell RA, Mak TW, Lindsten T, et al. BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol Cell 2001;8:705-11.
80. Cheng EH, Levine B, Boise LH, Thompson CB, Hardwick JM. Bax- Independent inhibition of apoptosis by Bcl-XL. Nature 1996;379: 554-6.
81. Kelekar A, Chang BS, Harlan JE, Fesik SW, Thompson CB. Bad is a BH3 domain-containing protein that forms an inactivating dimer with Bcl-XL. Mol Cell Biol 1997;17:7040-6.
82. Kelekar A, Thompson CB. Bcl-2-family proteins: the role of the BH3 domain in apoptosis. Trends Cell Biol 1998;8:324-30.
83. Sattler M, Liang H, Nettesheim D, Meadows RP, Harlan JE, Erbstadt M, et al. Structure of Bcl-XL-Bak peptide complex: recognition between regulators of apoptosis. Science 1997;275:983-6.
84. Saito M, Novak U, Piovan E, Basso K, Sumazin P, Schneider C, et al. BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B cell lymphoma. Proc Natl Acad Sci U S A 2009;27:11294-9.
85. Viatour P, Bentires-Alj M, Chariot A, Deregowski V, de Leval L, Merville MP, et al. NF-kappa B2/p100 induces Bcl-2 expression. Leukemia 2003;17:1349-56.
86. Pro B, Leber B, Smith M, Fayad L, Romaguera J, Hagemeister F, et al. Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma. Br J Haematol 2008;143: 355-60.
87. Wilson W, O'Connor O, Roberts AW, Czuczman M, Brown J, Xiong H, et al. ABT-263 activity and safety in patients with relapsed or refractory lymphoid malignancies in particular chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). J Clin Oncol 2009;27:15S.
88. Yecies D, Carlson NE, Deng J, Letai A. Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood 2010;115:3304-13.
89. Deng J, Carlson N, Taleyama K, Cin PD, Shipp MA, Letai A. BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell 2007;12:171-85.
90. Gilmore TD. Multiple mutations contribute to the oncogenicity of the retroviral oncoprotein v-Rel. Oncogene 1999;18:6925-37.
91. Thomas RK, Wickenhauser C, Tawadros S, Diehl V, Küppers R, Wolf J, et al. Mutational analysis of the IkappaBalpha gene in activated B cell-like diffuse large B-cell lymphoma. Br J Haematol 2004;126: 50-4.
92. Fan CM, Maniatis T. Generation of p50 subunit of NF-kappa B by processing of p105 through an ATP-dependent pathway. Nature 1991;354:395-8.
93. Mercurio F, DiDonato J, Rosette C, Karin M. Molecular cloning and characterization of a novel Rel/NF-kappa Bfamilymember displaying structural and functional homology to NF-kappa B p50/p105. DNA Cell Biol 1992;11:523-37.
94. Baeuerle PA, Baltimore D. A 65-kappaD subunit of active NF-kappaB is required for inhibition of NF-kappaB by I kappaB. Cell 1989;3: 1689-98.
95. Ryseck RP, Bull P, Takamiya M, Bours V, Siebenlist U, Dobrzanski P, et al. RelB, a new Rel family transcription activator that can interact with p50-NF-kappa B. Mol Cell Biol 1992;12:674-84.
96. Bull P, Morley KL, Hoekstra MF, Hunter T, Verma IM. The mouse c-rel protein has an N-terminal regulatory domain and a C-terminal transcriptional transactivation domain. Mol Cell Biol 1990;10:5473-85.
97. Baeuerle PA, Baltimore D. I kappa B: a specific inhibitor of the NFkappa B transcription factor. Science 1988;242:540-6.
98. Régnier CH, Song HY, Gao X, Goeddel DV, Cao Z, Rothe M. Identification and characterization of an IkappB kinase. Cell 1997;90: 373-83.
99. Gerondakis S, Grumont R, Rourke I, Grossmann M. The regulation and roles of Rel/NF-kappa B transcription factors during lymphocyte activation. Curr Opin Immunol 1998;10:353-9.
100. Grossmann M, Nakamura Y, Grumont R, Gerondakis S. New insights into the roles of ReL/NF-kappa B transcription factors in immune function, hemopoiesis and human disease. Int J Biochem Cell Biol 1999;31:1209-19.
101. Gugasyan R, Grumont R, Grossmann M, Nakamura Y, Pohl T, Nesic D, et al. Rel/NF-kappaB transcription factors: key mediators of B-cell activation. Immunol Rev 2000;176:134-40.
102. Monroe JG. ITAM-mediated tonic signalling through pre-BCR and BCR complexes. Nat Rev Immunol 2006;6:283-94.
103. Sommer K, Guo B, Pomerantz JL, Bandaranayake AD, Moreno- Garcia ME, Ovechkina YL, et al. Phosphorylation of the CARMA1 linker controls NF-kappaB activation. Immunity 2005;23:561-74.
104. Janssens S, Beyaert R. Functional diversity and regulation of different interleukin-1 receptor-associated kinase (IRAK) familymembers. Mol Cell 2003;11:293-302.
105. Fujihara M, Muroi M, Tanamoto K, Suzuki T, Azuma H, Ikeda H. Molecular mechanisms of macrophage activation and deactivation by lipopolysaccharide: roles of the receptor complex. Pharmacol Ther 2003;100:171-94.
106. Li S, Strelow A, Fontana EJ, Wesche H. IRAK-4: a novel member of the IRAK family with the properties of an IRAK-kinase. Proc Natl Acad Sci U S A 2002 99:5567-72.
107. Cao Z, Xiong J, Takeuchi M, Kurama T, Goeddel DV. TRAF6 is a signal transducer for interleukin-1. Nature 1996;383:443-6.
108. Lenz G, Davis RE, Ngo VN, Lam L, George TC, Wright GW, et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 2008;319:1676-9.
109. Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, et al. Chronic activate B-cell-receptor signaling in diffuse large B-cell lymphoma. Nature 2010;463:88-92.
110. Houldsworth JS, Mathew PH, Rao K, Dyomina DC, Louie N, Parsa K, et al.RELproto-oncogene is frequentlyamplified in extranodal diffuse large cell lymphoma. Blood 1996;87:25-29.
111. Jardin F, Ruminy P, Kerckaert JP, Parmentier F, Picquenot JM, Quief S, et al. Detection of somatic quantitative genetic alterations by multiplex polymerase chain reaction for the prediction of outcome in diffuse large B-cell lymphomas. Haematologica 2008;93:543-50.
112. Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q, et al. Mutations of multiple genes cause deregulation of NFkappaB in diffuse large B-cell lymphoma. Nature 2009;459:717-21.
113. Kato M, Sanada M, Kato I, Sato Y, Takita J, Takeuchi K, et al. Frequent inactivation of A20 in B-cell lymphomas. Nature 2009;459:712-6.
114. Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011;470:115-9.
115. Lam LT, Davis RE, Pierce J, Hepperle M, Xu Y, Hottelet M, et al. Small molecule inhibitors of IkappaBkinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res 2005;11:28-40.
116. Chen G, Cao P, Goeddel DV. TNF-induced recruitment and activation of the IKK complex require Cdc37 and Hsp90. Mol Cell 2002;2: 9401-10.
117. Dunleavy K, Pittaluga S, Czuczman MS, Dave SS, Wright G, Grant N, et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 2009;113:6069-79.
118. Delsol G, Lamant L, Mariamé B, Pulford K, Dastugue N, Brousset P, et al. A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2;5 translocation. Blood 1997;89:1483-90.
119. Li K, Tipps A, Wang H. Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma presenting as an isolated nasopharyngeal mass: a case report and review of literature. Int J Clin Exp Pathol 2010;4:190-6.
120. Laurent C, Do C, Gascoyne R, Lamant L, Ysebaert L, Laurent G, et al. Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis. J Clin Oncol 2009;27:4211-6.
121. De Paepe P, Baens M, van Krieken H, Verhasselt B, Stul M, Simons A, et al. ALK activation by the CLTC-ALK-Clathrin fusion is a recurrent event in large B-cell lymphoma. Blood 2003;102:2638-41.
122. Gascoyne RD, Lamant L, Martin-Subero JI, Lestou VS, Harris NL, Müller-Hermelink HK, et al. ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases. Blood 2003;102:2568-73.
123. Cerchietti L, Damm-Welk C, Vater I, Klapper W, Harder L, Pott C, et al. Inhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomas. PLoS One. 2011;6:e18436.
124. Kasprzycka M, Marzec M, Liu X, Zhang Q, Wasik MA. Nucleophosmin/ anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3. Proc Natl Acad Sci U S A 2006;103:9964-9.
125. Chiarle R, Simmons WJ, Cai H, Dhall G, Zamo A, Raz R, et al. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med 2005;11:623-9.
126. Bai RY, Ouyang T, Miething C, Morris SW, Peschel C, Duyster J. Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. Blood 2000;96: 4319-27.
127. Naylor TL, Tang H, Ratsch BA, Enns A, Loo A, Chen L, et al. Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas. Cancer Res 2011;71: 2643-53.
128. Pasqualucci L, Trifonov V, Fabbri G, Ma J, Rossi D, Chiarenza A, et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet 2011;43:830-7.
129. Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall K, Corbett RD, et al. Frequent mutation of histone-modifying genes in non- Hodgkin lymphoma. Nature 2011;476:298-303.
130. Pasqualucci L, Dominguez-Sola D, Chiarenza A, Fabbri G, Grunn A, Trifonov V, et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 2011;471:189-95.
131. Bereshchencko OR, Gu W, Dalla-Favera R. Acetylation inactivates the transcriptional repressor BCL6. Nat Genet 2002;32: 606-13.
132. Challa-Malladi M, Lieu YK, Califano O, Holmes AB, Bhagat G, Murty VV, et al. Combined genetic inactivation of β2-microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. Cancer Cell 2011;20:728-40.
133. Sanchez-Madrid F, Krensky AM, Ware CF, Robbins E, Strominger JL, Burakoff SJ, et al. Three distinct antigens associated with human Tlymphocyte- mediated cytolysis: LFA-1, LFA-2, and LFA-3. Proc Natl Acad Sci U S A 1982;79:7489-93.
134. Selvaraj P, Plunkett ML, Dustin M, Sanders ME, Shaw S, Springer TA. The T lymphocyte glycoproteinCD2binds the cell surface ligand LFA- 3. Nature 1987;326:400-3.
135. Poulik MD, Reisfeld RA. Beta2-microglobulins. Contemp Top Mol Immunol 1975;4:157-204.
136. Li C, Kim S, Rai D, Bolla AR, Adhvaryu S, Kinney MC, et al. Copy number abnormalities, MYC activity, and the genetic fingerprint of normal B cells mechanistically define the microRNA profile off diffuse large B-cell lymphoma. Blood 2009;113:6681-90.
137. Cho WC. OncomiRs: the discovery and progress of microRNAs in cancers. Mol Cancer 2007;6:60.
138. Medina P, Nolde M, Slack F. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature 2010;467: 86-90.
139. Rai D, Karanti S, Jung I, Dahia P, Aguiar R. Coordinated expression of microRNA-155 and predicted target genes in diffuse large B-cell lymphoma. Cancer Genet Cytogenet 2009;181:8-15.
140. Lowery AJ, Miller N, McNeill RE, Kerin MJ. MicroRNAs as prognostic indicators and therapeutic targets: potential effect on breast cancer management. Clin Cancer Res 2008;14:360-5.